ClinVar Miner

Submissions for variant NM_000535.7(PMS2):c.2500_2501delinsG (p.Met834fs)

dbSNP: rs587781626
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 7
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000129728 SCV000184533 pathogenic Hereditary cancer-predisposing syndrome 2022-02-01 criteria provided, single submitter clinical testing The c.2500_2501delATinsG pathogenic mutation, located in coding exon 15 of the PMS2 gene, results from the deletion of two nucleotides and insertion of one nucleotide causing a translational frameshift with a predicted alternate stop codon (p.M834Gfs*17). This alteration occurs at the 3' terminus of thePMS2 gene, is not expected to trigger nonsense-mediated mRNA decay, and only impacts the last 29 amino acids of the protein. However, premature stop codons are typically deleterious in nature and the impacted region is critical for protein function (Ambry internal data). This mutation has been reported in individuals with hereditary non-polyposis colorectal cancer (HNPCC)/Lynch syndrome, including multiple probands whose Lynch syndrome-associated tumors demonstrated loss of PMS2 expression by immunohistochemistry (Espenschied CR et al. J Clin Oncol, 2017 Aug;35:2568-2575; Carter NJ et al. Gynecol Oncol, 2018 12;151:481-488; Roberts ME et al. Genet Med, 2018 10;20:1167-1174; Lerner-Ellis J et al. J Cancer Res Clin Oncol, 2021 Mar;147:871-879; Ambry internal data). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation.
Invitae RCV000469291 SCV000551942 pathogenic Hereditary nonpolyposis colorectal neoplasms 2024-01-05 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Met834Glyfs*17) in the PMS2 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 29 amino acid(s) of the PMS2 protein. The frequency data for this variant in the population databases (gnomAD) is considered unreliable due to the presence of homologous sequence, such as pseudogenes or paralogs, in the genome. This premature translational stop signal has been observed in individual(s) with clinical features of constitutional mismatch repair deficiency syndrome (CMMR-D) and/or clinical features of Lynch syndrome (PMID: 23012243, 25856668, 28514183, 30322717; Scientific presentation). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 141280). This variant disrupts the MLH1 interaction domain of the PMS2 protein, which has been shown to be critical for PMS2-MLH1 dimerization (PMID: 10037723), and therefore mismatch repair activity (PMID: 16338176, 20533529). While functional studies have not been performed to directly test the effect of this variant on PMS2 protein function, this suggests that disruption of this region of the protein is causative of disease. For these reasons, this variant has been classified as Pathogenic.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000587959 SCV000697350 pathogenic Hereditary nonpolyposis colon cancer 2022-11-14 criteria provided, single submitter clinical testing Variant summary: PMS2 c.2500_2501delinsG (p.Met834GlyfsX17) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as likely pathogenic by our laboratory. The variant was absent in 145224 control chromosomes (gnomAD). c.2500_2501delinsG has been reported in the literature in individuals affected with Lynch Syndrome and associated cancers (Carter_2018, Espenschied_2017, Goodenberger_2015, LaDuca_2017). These data indicate that the variant is likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Three ClinVar submissions (evaluation after 2014) cite this variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000759203 SCV000888410 pathogenic not provided 2018-08-05 criteria provided, single submitter clinical testing
Myriad Genetics, Inc. RCV003453066 SCV004187689 pathogenic Lynch syndrome 4 2023-09-25 criteria provided, single submitter clinical testing This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation.
Color Diagnostics, LLC DBA Color Health RCV000129728 SCV004358964 pathogenic Hereditary cancer-predisposing syndrome 2023-04-19 criteria provided, single submitter clinical testing This variant alters 2 nucleotides in exon 15 of the PMS2 gene, creating a frameshift at codon 834 and a premature stop at codon 850. While this variant is not expected to trigger nonsense-mediated decay, a truncated C-terminal polypeptide (lacking a.a. 826-850) has previously been shown to lack binding to MLH1 (PMID: 10037723) and single missense mutations in codons 843, 845 and 847 have been shown to disrupt DNA mismatch repair in vitro (PMID: 18619468). This variant is expected to result in a non-functional protein product. This variant has been reported in multiple individuals affected with Lynch syndrome-associated cancer (PMID: 23012243, 25856668, 28514183, 30322717). Moreover, further C-terminal truncation at codon 836 and a frameshift at codon 841 have been observed in an individual suspected of Lynch syndrome (PMID: 28514183) and individuals affected with biallelic constitutional mismatch repair deficiency syndrome (PMID: 26116798, 30764633), respectively. This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Based on the available evidence, this variant is classified as Pathogenic.
Department of Pathology and Laboratory Medicine, Sinai Health System RCV001355078 SCV001549848 pathogenic Carcinoma of colon no assertion criteria provided clinical testing The PMS2 p.Met834Glyfs*17 variant was identified in 3 of 69960 proband chromosomes (frequency: 0.00004) from individuals or families with Lynch Syndrome (Espenschied 2017). The variant was also identified in ClinVar (classified as pathogenic by Ambry Genetics, Invitae), Clinvitae (classified as pathogenic by ClinVar), Insight Hereditary Tumors Database, databases. The variant was not identified in dbSNP, Insight Colon Cancer Gene Variant Database, Zhejiang Colon Cancer Database, Mismatch Repair Genes Variant Database, databases. The variant was not identified in the 1000 Genomes Project, the NHLBI GO Exome Sequencing Project or the Exome Aggregation Consortium (August 8th 2016) control databases. The c.2500_2501delinsG variant is predicted to cause a frameshift, which alters the protein's amino acid sequence beginning at codon 834 and leads to a premature stop codon at position 850. This alteration is then predicted to result in a truncated or absent protein and loss of function. Loss of function variants of the PMS2 gene are an established mechanism of disease in Lynch Syndrome and is the type of variant expected to cause the disorder. In summary, based on the above information, this variant meets our laboratory’s criteria to be classified as pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.